The agency warned healthcare providers against giving remdesivir to patients at the same time as hydroxychloroquine or chloroquine, saying the combination could result in the “reduced antiviral activity of remdesivir.”
The FDA withdrew its emergency use authorizations for hydroyxychloroquine and chloroquine June 15 because research hasn’t proven them to be effective in preventing or treating COVID-19.
The agency updated the fact sheet for remdesivir with the new warning as well as with information about possible allergic reactions.
Read the FDA’s full news release here.
More articles on pharmacy:
FDA rescinds hydroxychloroquine emergency use authorization
6 recent drug, device recalls
10 exec moves affecting the pharma industry
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
